SEC Form 4 · accession 0001209191-17-041790
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerrit Dispersyn
Officer — Chief Development Officer
Period of report
Jun 23, 2017
Accepted (ET)
Jun 26, 2017 · 8:23 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Jun 23, 2017 | P | 3,500 | $0.62 | A | 3,500 | D |
Table II — derivative securities
No Table II lines on this filing.